Table 4.

Influence of dialysate calcium concentration and use of calcium-containing phosphate binders on PTH reduction mixed-effects model analysis

Summary of ChangesCinacalcetVitamin D AnalogTreatment DifferenceP Value
Dialysate calcium ≥2.5 mEq/L
 No. of participants101106
 Mean change in PTH (%)−18.9 (−28.0 to −9.9)−6.0 (−15.1 to 3.1)−12.9 (−25.4 to −0.5)0.04
 Dosing during EAP82.9 (53.69)a17.6 (10.92)b
Dialysate calcium <2.5 mEq/L
 No. of participants5250
 Mean change in PTH (%)4.8 (−21.0 to 30.5)−7.6 (−33.2 to 18.0)12.4 (−6.6 to 31.3)0.20
 Dosing during EAP83.6 (50.29)a23.5 (12.77)b
Calcium-based phosphate binder used
 No. of participants6173
 Mean change in PTH (%)−16.1 (−29.0 to −3.3)1.2 (−10.6 to 13.0)−17.3 (−34.2 to −0.4)0.04
Calcium-based phosphate binder not used
 No. of participants9484
 Mean change in PTH (%)−9.2 (−19.4 to 0.9)−14.3 (−25.1 to −3.5)5.0 (−8.2 to 18.2)0.45
  • Data are given as the mean (SD) or mean (95% confidence interval). PTH, parathyroid hormone; EAP, efficacy assessment phase.

  • a Cinacalcet dosage in milligrams per day.

  • b Vitamin D analog dosage expressed as paricalcitol equivalent units per week.